Patents by Inventor Anhui GAO

Anhui GAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bruton's tyrosine kinase inhibitors
    Patent number: 11974999
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: January 1, 2021
    Date of Patent: May 7, 2024
    Assignees: Suzhou Baijibugong Pharmaceutical Technology Co., Ltd.
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof
    Publication number: 20230295144
    Abstract: The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Application
    Filed: January 24, 2023
    Publication date: September 21, 2023
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • MACROCYCLIC JAK INHIBITOR AND USES THEREOF
    Publication number: 20230203059
    Abstract: The present invention relates to a macrocyclic JAK inhibitor and the uses thereof. Specifically, the present invention relates to a compound represented by formula I, or a stereoisomer or an optical isomer, a pharmaceutically acceptable salt, or a prodmg or a solvate thereof; and also relates to a pharmaceutical composition of the compound, and the medical uses thereof as a JAK inhibitor and in the preparation of a drug for preventing and/or treating diseases related to JAK, especially JAK3.
    Type: Application
    Filed: May 21, 2021
    Publication date: June 29, 2023
    Inventors: Zhijian LV, Jia LI, Mingbo SU, Anhui GAO
  • MACROCYCLIC JAK INHIBITOR AND USE THEREOF
    Publication number: 20230167114
    Abstract: The present invention relates to a macrocyclic JAK inhibitor and the use thereof. The present invention specifically relates to a compound as shown in formula I, or a stereoisomer or optical isomer thereof, a pharmaceutically acceptable salt thereof, and a prodrug or solvate thereof, and also relates to a pharmaceutical composition of the compound and the medical use thereof as a JAK inhibitor, and in the preparation of medicaments for preventing and/or treating diseases related to JAK, especially JAK1.
    Type: Application
    Filed: May 21, 2021
    Publication date: June 1, 2023
    Inventors: Zhijian LV, Jia LI, Mingbo SU, Anhui GAO
  • 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof
    Patent number: 11591325
    Abstract: The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: February 28, 2023
    Assignees: ZHEJIANG UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • Bruton's tyrosine kinase inhibitors
    Patent number: 11554118
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: January 17, 2023
    Assignees: SUZHOU BAIJIBUGONG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof
    Publication number: 20210284625
    Abstract: The present invention provides a 2-polysubstituted aromatic ring-pyrimidine derivative and an optical isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, the compound, and an optical isomer thereof or a pharmaceutically thereof acceptable salts or solvates can be used in the preparation of anti-tumor drugs. The invention designs and synthesizes a series of novel small molecule Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained by structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess potent anticancer activity, Chk1 kinase inhibitory activity, and are promising Chk1 inhibitors, and can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Application
    Filed: November 8, 2017
    Publication date: September 16, 2021
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20210121458
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: January 1, 2021
    Publication date: April 29, 2021
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20210107903
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: March 21, 2018
    Publication date: April 15, 2021
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Bruton's tyrosine kinase inhibitors
    Patent number: 10933063
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: March 2, 2021
    Assignees: Suzhou Baijibugong Pharmaceutical Technology Co., Ltd.
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • 2-substituted aromatic ring-pyrimidine derivative and preparation and application thereof
    Patent number: 10822327
    Abstract: A 2-substituted aromatic ring-pyrimidine derivative as shown in a general formula I, and an optical isomer or a pharmaceutically acceptable salt or a solvate thereof are provided. The present invention designs and synthesizes a series of novel small molecular Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained through structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess strong anti-cancer effect, Chk1 kinase inhibitory activity and are promising Chk1 inhibitors. The compounds can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: November 3, 2020
    Assignees: ZHEJIANG UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • Bruton's tyrosine kinase inhibitors
    Patent number: 10793566
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: October 6, 2020
    Assignees: ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Aryl-2,2?-tandem bisthiazole compound and preparation method and use thereof
    Patent number: 10766889
    Abstract: The invention describes an aryl-2,2?-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2?-tandem bisthiazole compound with the structure as shown in general formula I and the preparation method thereof and use thereof as a histone deacetylase inhibitor in the preparation of antitumor drugs.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: September 8, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Fajun Nan, Jia Li, Jian Ding, Meiyu Geng, Yangming Zhang, Yi Chen, Yubo Zhou, Chaojun Gong, Mingbo Su, Anhui Gao
  • Bruton's tyrosine kinase inhibitors
    Patent number: 10662187
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: May 26, 2020
    Assignees: Zibo Biopolar Changsheng Pharmaceutical Co. Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • 2-substituted aromatic ring-pyrimidine derivative and preparation and application thereof
    Publication number: 20190375727
    Abstract: A 2-substituted aromatic ring-pyrimidine derivative as shown in a general formula I, and an optical isomer or a pharmaceutically acceptable salt or a solvate thereof are provided. The present invention designs and synthesizes a series of novel small molecular Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained through structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess strong anti-cancer effect, Chk1 kinase inhibitory activity and are promising Chk1 inhibitors. The compounds can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Application
    Filed: November 8, 2017
    Publication date: December 12, 2019
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20190275037
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20190276453
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Bruton's tyrosine kinase inhibitors
    Patent number: 10358446
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: July 23, 2019
    Assignees: ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • ARYL-2,2'-TANDEM BISTHIAZOLE COMPOUND AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20190211005
    Abstract: The invention describes an aryl-2,2?-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2?-tandem bisthiazole compound with the structure as shown in general formula I and the preparation method thereof and use thereof as a histone deacetylase inhibitor in the preparation of antitumor drugs.
    Type: Application
    Filed: August 24, 2017
    Publication date: July 11, 2019
    Inventors: Fajun NAN, Jia LI, Jian DING, Meiyu GENG, Yangming ZHANG, Yi CHEN, Yubo ZHOU, Chaojun GONG, Mingbo SU, Anhui GAO
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20190062328
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: January 17, 2017
    Publication date: February 28, 2019
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO